SPARINGVISION
π«π·France
- Country
- π«π·France
- Ownership
- -
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://sparingvision.com
Promising ROd-cone DYstrophy Gene therapY
Phase 1
Recruiting
- Conditions
- Retinitis Pigmentosa
- Interventions
- Drug: SPVN06
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- SparingVision
- Target Recruit Count
- 33
- Registration Number
- NCT05748873
- Locations
- πΊπΈ
Bascom Palmer Eye Institute/University of Miami, Miami, Florida, United States
πΊπΈCasey Eye Institute, Portland, Oregon, United States
πΊπΈUPMC Eye Center, Pittsburgh, Pennsylvania, United States
Prospective Natural History Study of Retinitis Pigmentosa
Not Applicable
Active, not recruiting
- Conditions
- Retinitis Pigmentosa
- Interventions
- Other: Ophthalmic examinationsOther: Mobility Test
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- SparingVision
- Target Recruit Count
- 82
- Registration Number
- NCT04285398
- Locations
- π«π·
CHNO XV-XX Paris - CIC 1423, Paris, France
πΊπΈUPMC Eye Center, Pittsburgh, Pennsylvania, United States
Retrospective Natural History Study of Retinitis Pigmentosa
- Conditions
- Retinitis Pigmentosa (RP)
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- SparingVision
- Target Recruit Count
- 113
- Registration Number
- NCT03975543
- Locations
- π«π·
CHNO XV-XX Paris - CIC 1423, Paris, France
Β© Copyright 2025. All Rights Reserved by MedPath